Therapeutic drug monitoring and tyrosine kinase inhibitors (Review)

Herviou,Pauline; Thivat,Emilie; Richard,Damien; Roche,Lucie; Dohou,Joyce; Pouget,Mélanie; Eschalier,Alain; Durando,Xavier; Authier,Nicolas

doi:10.3892/ol.2016.4780

Therapeutic drug monitoring and tyrosine kinase inhibitors (Review)

Authors:
- Pauline Herviou
- Emilie Thivat
- Damien Richard
- Lucie Roche
- Joyce Dohou
- Mélanie Pouget
- Alain Eschalier
- Xavier Durando
- Nicolas Authier
View Affiliations

Affiliations: Department of Pharmacology, CHU Clermont‑Ferrand, Clermont‑Ferrand F‑63003, France, Centre Jean Perrin, Clermont‑Ferrand F‑63011, France
Published online on: June 24, 2016 https://doi.org/10.3892/ol.2016.4780
Pages: 1223-1232

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The therapeutic activity of drugs can be optimized by establishing an individualized dosage, based on the measurement of the drug concentration in the serum, particularly if the drugs are characterized by an inter‑individual variation in pharmacokinetics that results in an under- or overexposure to treatment. In recent years, several tyrosine kinase inhibitors (TKIs) have been developed to block intracellular signaling pathways in tumor cells. These oral drugs are candidates for therapeutic drug monitoring (TDM) due to their high inter‑individual variability for therapeutic and toxic effects. Following a literature search on PubMed, studies on TKIs and their pharmacokinetic characteristics, plasma quantification and inter‑individual variability was studied. TDM is commonly used in various medical fields, including cardiology and psychiatry, but is not often applied in oncology. Plasma concentration monitoring has been thoroughly studied for imatinib, in order to evaluate the usefulness of TDM. The measurement of plasma concentration can be performed by various analytical techniques, with liquid chromatography-mass spectrometry being the reference method. This method is currently used to monitor the efficacy and tolerability of imatinib treatments. Although TDM is already being used for imatinib, additional studies are required in order to improve this practice with the inclusion of other TKIs.

View Figures

View References

1	McLeod HL: Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther. 74:39–54. 1997. View Article : Google Scholar : PubMed/NCBI
2	Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH and Huitema AD: Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: Focus on the pharmacokinetic targets. Clin Pharmacokinet. 53:305–325. 2014. View Article : Google Scholar : PubMed/NCBI
3	de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S and Beijnen JH: Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review. Clin Pharmacokinet. 44:147–173. 2012. View Article : Google Scholar
4	Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J and Sparreboom A: Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: Does it make a difference? Oncologist. 12:913–923. 2007. View Article : Google Scholar : PubMed/NCBI
5	Arora A and Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 315:971–979. 2005. View Article : Google Scholar : PubMed/NCBI
6	Josephs DH, Fisher DS, Spicer J and Flanagan RJ: Clinical pharmacokinetics of tyrosine kinase inhibitors: Implications for therapeutic drug monitoring. Ther Drug Monit. 35:562–587. 2013.PubMed/NCBI
7	Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G and Astier A: Review of therapeutic drug monitoring of anticancer drugs part two - targeted therapies. Eur J Cancer. 50:2020–2036. 2014. View Article : Google Scholar : PubMed/NCBI
8	van Erp NP, Gelderblom H and Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 35:692–706. 2009. View Article : Google Scholar : PubMed/NCBI
9	Teo YL, Ho HK and Chan A: Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: Current understanding, challenges and recommendations. Br J Clin Pharmacol. 79:241–253. 2015. View Article : Google Scholar : PubMed/NCBI
10	Apperley JF: Part II: Management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8:1116–1128. 2007. View Article : Google Scholar : PubMed/NCBI
11	Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, et al: Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 27:107–112. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109:2303–2309. 2007. View Article : Google Scholar : PubMed/NCBI
13	Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, et al: Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 14:352–359. 2008. View Article : Google Scholar : PubMed/NCBI
14	Mathisen MS, Kantarjian HM, Cortes J and Jabbour EJ: Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 28:179–187. 2014. View Article : Google Scholar : PubMed/NCBI
15	Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, et al: Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib (erratum). Blood. 122:25242013.
16	Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar : PubMed/NCBI
17	Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N and Decosterd LA: Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 877:1982–1996. 2009. View Article : Google Scholar : PubMed/NCBI
18	Pirro E, De Francia S, De Martino F, Fava C, Ulisciani S, Cambrin GR, Racca S, Saglio G and Di Carlo F: A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. J Chromatogr Sci. 49:753–757. 2011. View Article : Google Scholar : PubMed/NCBI
19	Saita T, Shin M and Fujito H: Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib. Biol Pharm Bull. 36:1964–1968. 2013. View Article : Google Scholar : PubMed/NCBI
20	Götze L, Hegele A, Metzelder SK, Renz H and Nockher WA: Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta. 413:143–149. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ajimura TO, Borges KB, Ferreira AF, de Castro FA and de Gaitani CM: Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients. Electrophoresis. 32:1885–1892. 2011. View Article : Google Scholar : PubMed/NCBI
22	Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MM, Nardinelli L, Costa AL, Chamone DA and Bendit I: Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: Validation and application of a new analytical method to monitor treatment compliance. Rev Bras Hematol Hemoter. 35:103–108. 2013. View Article : Google Scholar : PubMed/NCBI
23	Roth O, Spreux-Varoquaux O, Bouchet S, Rousselot P, Castaigne S, Rigaudeau S, Raggueneau V, Therond P, Devillier P, Molimard M and Maneglier B: Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. Clin Chim Acta. 411:140–146. 2010. View Article : Google Scholar : PubMed/NCBI
24	Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J and Decosterd LA: Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 803:285–292. 2004. View Article : Google Scholar : PubMed/NCBI
25	Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L and Gupta SK: Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci. 804:431–434. 2004. View Article : Google Scholar : PubMed/NCBI
26	Bende G, Kollipara S, Movva S, Moorthy G and Saha R: Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study. J Chromatogr Sci. 48:334–341. 2010. View Article : Google Scholar : PubMed/NCBI
27	Pursche S, Ottmann OG, Ehninger G and Schleyer E: High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. J Chromatogr B Analyt Technol Biomed Life Sci. 852:208–216. 2007. View Article : Google Scholar : PubMed/NCBI
28	Miura M, Takahashi N and Sawada K: High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma. Biomed Chromatogr. 24:789–793. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yuki M, Yamakawa Y, Uchida T, Nambu T, Kawaguchi T, Hamada A and Saito H: High-performance liquid chromatographic assay for the determination of nilotinib in human plasma. Biol Pharm Bull. 34:1126–1128. 2011. View Article : Google Scholar : PubMed/NCBI
30	Davies A, Hayes AK, Knight K, Watmough SJ, Pirmohamed M and Clark RE: Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res. 34:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
31	Faivre L, Gomo C, Mir O, Taieb F, Schoemann-Thomas A, Ropert S, Vidal M, Dusser D, Dauphin A, Goldwasser F and Blanchet B: A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 879:2345–2350. 2011. View Article : Google Scholar : PubMed/NCBI
32	Afify S, Rapp UR and Högger P: Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43–9006 in small volumes of mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci. 809:99–103. 2004. View Article : Google Scholar : PubMed/NCBI
33	Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F and Tod M: Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 49:1109–1114. 2009. View Article : Google Scholar : PubMed/NCBI
34	Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F and Tod M: Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta. 404:134–139. 2009. View Article : Google Scholar : PubMed/NCBI
35	Zhen Y, Thomas-Schoemann A, Sakji L, Boudou-Rouquette P, Dupin N, Mortier L, Vidal M, Goldwasser F and Blanchet B: An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci. 928:93–97. 2013. View Article : Google Scholar : PubMed/NCBI
36	Jones HK, Stafford LE, Swaisland HC and Payne R: A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: Validation and use in Phase I clinical trials. J Pharm Biomed Anal. 29:221–228. 2002. View Article : Google Scholar : PubMed/NCBI
37	Rezende VM, Rivellis A, Novaes MM, de Alencar Fisher, Chamone D and Bendit I: Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Des Devel Ther. 7:699–710. 2013. View Article : Google Scholar : PubMed/NCBI
38	De Francia S, D'Avolio A, De Martino F, Pirro E, Baietto L, Siccardi M, Simiele M, Racca S, Saglio G, Di Carlo F and Di Perri G: New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 877:1721–1726. 2009. View Article : Google Scholar : PubMed/NCBI
39	Sparidans RW, Iusuf D, Schinkel AH, Schellens JH and Beijnen JH: Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 877:4090–4096. 2009. View Article : Google Scholar : PubMed/NCBI
40	Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L and Stouffer B: A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 58:130–135. 2012. View Article : Google Scholar : PubMed/NCBI
41	Zhao M, He P, Rudek MA, Hidalgo M and Baker SD: Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 793:413–420. 2003. View Article : Google Scholar : PubMed/NCBI
42	Masters AR, Sweeney CJ and Jones DR: The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 848:379–383. 2007. View Article : Google Scholar : PubMed/NCBI
43	Thappali SR, Varanasi K, Veeraraghavan S, Arla R, Chennupati S, Rajamanickam M, Vakkalanka S and Khagga M: Simultaneous determination of celecoxib, erlotinib, and its metabolite desmethyl-erlotinib (OSI-420) in rat plasma by liquid chromatography/tandem mass spectrometry with positive/negative ion-switching electrospray ionisation. Sci Pharm. 80:633–646. 2012. View Article : Google Scholar : PubMed/NCBI
44	Wang LZ, Lim MY, Chin TM, Thuya WL, Nye PL, Wong A, Chan SY, Goh BC and Ho PC: Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 879:2155–2161. 2011. View Article : Google Scholar : PubMed/NCBI
45	Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF and Ruiz-Nuño A: Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma. Biomed Chromatogr. 27:502–508. 2013. View Article : Google Scholar : PubMed/NCBI
46	Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P, Mahon FX and Molimard M: Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 27:634–640. 2005. View Article : Google Scholar : PubMed/NCBI
47	Bianchi F, Caffarri E, Cavalli S, Lagrasta C, Musci M, Quaini F and Savi M: Development and validation of an high performance liquid chromatography-tandem mass spectrometry method for the determination of imatinib in rat tissues. J Pharm Biomed Anal. 73:103–107. 2013. View Article : Google Scholar : PubMed/NCBI
48	Bakhtiar R, Khemani L, Hayes M, Bedman T and Tse F: Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 28:1183–1194. 2002. View Article : Google Scholar : PubMed/NCBI
49	Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M and Tse F: High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 768:325–340. 2002. View Article : Google Scholar : PubMed/NCBI
50	Parise RA, Ramanathan RK, Hayes MJ and Egorin MJ: Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 791:39–44. 2003. View Article : Google Scholar : PubMed/NCBI
51	Bai F, Freeman BB III, Fraga CH, Fouladi M and Stewart CF: Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 831:169–175. 2006. View Article : Google Scholar : PubMed/NCBI
52	Minocha M, Khurana V and Mitra AK: Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). J Chromatogr B Analyt Technol Biomed Life Sci. 901:85–92. 2012. View Article : Google Scholar : PubMed/NCBI
53	Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H and Baker SD: Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 874:84–88. 2008. View Article : Google Scholar : PubMed/NCBI
54	Zhou Q and Gallo JM: Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 51:958–964. 2010. View Article : Google Scholar : PubMed/NCBI
55	Oberoi RK, Mittapalli RK, Fisher J and Elmquist WF: Sunitinib LC-MS/MS assay in mouse plasma and brain tissue: Application in CNS distribution studies. Chromatographia. 76:762013. View Article : Google Scholar
56	Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH and Sparidans RW: Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomed Chromatogr. 28:1366–1370. 2014. View Article : Google Scholar : PubMed/NCBI
57	Alvarez JC, Funck-Brentano E, Abe E, Etting I, Saiag P and Knapp A: A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. J Pharm Biomed Anal. 97:29–32. 2014. View Article : Google Scholar : PubMed/NCBI
58	Nijenhuis CM, Rosing H, Schellens JH and Beijnen JH: Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. J Pharm Biomed Anal. 88:630–635. 2014. View Article : Google Scholar : PubMed/NCBI
59	Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Walraven M, Lind JS, Tibaldi C, Verheul HM and Peters GJ: Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 878:1059–1068. 2010. View Article : Google Scholar : PubMed/NCBI
60	Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD and Beijnen JH: Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. J Anal Toxicol. 35:558–565. 2011. View Article : Google Scholar : PubMed/NCBI
61	Couchman L, Birch M, Ireland R, Corrigan A, Wickramasinghe S, Josephs D, Spicer J and Flanagan RJ: An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 403:1685–1695. 2012. View Article : Google Scholar : PubMed/NCBI
62	Veeraraghavan S, Thappali S, Viswanadha S, Chennupati S, Nalla S, Golla M, Vakkalanka S and Rangasamy M: Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. J Pharm Biomed Anal. 94:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
63	de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA and Loos WJ: Bioanalytical method for the quantification of sunitinib and its N-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 51:934–941. 2010. View Article : Google Scholar : PubMed/NCBI
64	Bihan K, Sauzay C, Goldwirt L, Charbonnier-Beaupel F, Hulot JS, Funck-Brentano C and Zahr N: Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: Application to a human pharmacokinetic study. Ther Drug Monit. 37:132–136. 2015. View Article : Google Scholar : PubMed/NCBI
65	Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, Titier K and Molimard M: Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta. 412:1060–1067. 2011. View Article : Google Scholar : PubMed/NCBI
66	van Erp NP, de Wit D, Guchelaar HJ, Gelderblom H, Hessing TJ and Hartigh J: A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 937:33–43. 2013. View Article : Google Scholar : PubMed/NCBI
67	Martins DH, Wagner SC, Dos Santos TV, Lizot LL, Antunes MV, Capra M and Linden R: Monitoring imatinib plasma concentrations in chronic myeloid leukemia. Rev Bras Hematol Hemoter. 33:302–306. 2011. View Article : Google Scholar : PubMed/NCBI
68	Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, et al: Phase I//II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small cell lung cancer. J Clin Oncol. 28:1387–1394. 2010. View Article : Google Scholar : PubMed/NCBI
69	Osterberg L and Blaschke T: Adherence to medication. N Engl J Med. 353:487–497. 2005. View Article : Google Scholar : PubMed/NCBI
70	Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 28:2381–2388. 2010. View Article : Google Scholar : PubMed/NCBI
71	Klümpen HJ, Samer CF, Mathijssen RH, Schellens JH and Gurney H: Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 37:251–260. 2011. View Article : Google Scholar : PubMed/NCBI
72	Opdam FL, Gelderblom H and Guchelaar HJ: Phenotyping drug disposition in oncology. Cancer Treat Rev. 38:715–725. 2012. View Article : Google Scholar : PubMed/NCBI
73	Pajares B, Torres E, Trigo JM, Sáez MI, Ribelles N, Jiménez B and Alba E: Tyrosine kinase inhibitors and drug interactions: A review with practical recommendations. Clin Transl Oncol. 14:94–101. 2012. View Article : Google Scholar : PubMed/NCBI
74	Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I and Wang Y: IRIS (International Randomized Interferon vs STI571) Study Group: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood. 111:4022–4028. 2008. View Article : Google Scholar : PubMed/NCBI
75	Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P and Capdeville R: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 22:935–942. 2004. View Article : Google Scholar : PubMed/NCBI
76	Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, et al: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 109:3496–3499. 2007. View Article : Google Scholar : PubMed/NCBI
77	Awidi A, Ayed AO, Bsoul N, Magablah A, Mefleh R, Dweiri M, Ramahi M, Arafat E, Bishtawi M and Marie L: Relationship of serum imatinib trough level and response in CML patients: Long term follow-up. Leuk Res. 34:1573–1575. 2010. View Article : Google Scholar : PubMed/NCBI
78	Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa K, Mitsuya H and Saito H: Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol. 89:642–648. 2009. View Article : Google Scholar : PubMed/NCBI
79	Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H and von Mehren M: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 27:3141–3147. 2009. View Article : Google Scholar : PubMed/NCBI
80	Delbaldo C, Chatelut E, Ré M, Deroussent A, Séronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY and Vassal G: Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 12:6073–6078. 2006. View Article : Google Scholar : PubMed/NCBI
81	Yoon S, Ryu MH, Yoo C, Beck MY, Ryoo BY and Kang YK: Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients. J Korean Med Sci. 28:1248–1252. 2013. View Article : Google Scholar : PubMed/NCBI
82	Baccarani M and Dreyling M: ESMO Guidelines Working Group: Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20(Suppl 4): S105–S107. 2009.
83	Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, Benz R, Leoncini-Franscini L, Baerlocher GM, Duchosal MA, et al: Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: Results from a randomized controlled trial. Cancer Chemother Pharmacol. 74:1307–1319. 2014. View Article : Google Scholar : PubMed/NCBI
84	Deininger MW: Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008:419–426. 2008.
85	Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 354:2542–2551. 2006. View Article : Google Scholar : PubMed/NCBI
86	Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT and Shah NP: Differential effects of dosing regimen on the safety and efficacy of dasatinib: Retrospective exposure-response analysis of a phase III study. Clin Pharmacol. 5:85–97. 2013.PubMed/NCBI
87	Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM and le Coutre PD: Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph⁺ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 68:723–733. 2012. View Article : Google Scholar : PubMed/NCBI
88	Nakamura Y, Sano K, Soda H, Takatani H, Fukuda M, Nagashima S, Hayashi T, Oka M, Tsukamoto K and Kohno S: Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol. 5:1404–1409. 2010. View Article : Google Scholar : PubMed/NCBI
89	Zhao YY, Li S, Zhang Y, Zhao HY, Liao H, Guo Y, Shi YX, Jiang W, Xue C and Zhang L: The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol. 28:697–702. 2011. View Article : Google Scholar : PubMed/NCBI
90	Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 24:25–35. 2006. View Article : Google Scholar : PubMed/NCBI